benzinga.com · 2 jul

Jim Cramer: 'Go For' AST SpaceMobile, Power Plant Maker 'Too Speculative'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Medline Inc. (NASDAQ:MDLN), adding that it is “probably the best IPO of the year.”

globenewswire.com · 1 jul

MDLN ALERT: HBSS Probes Medline (MDLN) After Reports Reveal Undisclosed Manufacturing Violations and Failed Contamination Investigations

SAN FRANCISCO, July 01, 2026 (GLOBE NEWSWIRE) -- National shareholder rights firm Hagens Berman Sobol Shapiro (HBSS) has launched an investigation into Medline Inc. (NASDAQ: MDLN) focusing on whether the company may have misled investors regarding the adequacy of its manufacturing quality controls and compliance with FDA safety standards. SUBMIT YOUR MDLN INVESTMENT LOSSES TO HBSS NOW The firm is looking into whether Medline concealed systemic lapses in its contamination protocols—specifically failures to investigate microbial incidents and batch discrepancies—that prompted regulatory scrutiny and triggered a significant decline in the company's share price.

globenewswire.com · 1 jul

Medline to report second quarter 2026 results on August 5, 2026

NORTHFIELD, Ill., July 01, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report second quarter 2026 financial results on Wednesday, August 5, 2026.

globenewswire.com · 30 jun

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Industries, Inc. - MDLN

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

seekingalpha.com · 30 jun

Medline: After IPO In 2025, This Year Is A Bet On Continued Growth

Medline Inc. is rated a buy, driven by robust sector macroeconomics, strong ROE, organic Q1 growth, and a favorable Fitch investment-grade rating. MDLN's top-line growth is compelling, with net sales up 10.7% YoY, fueled by new customer signings and international market penetration. Despite positive revenue trends, MDLN faces margin pressure from rising costs, volatile cash flows, and a rich 37x forward earnings multiple, warranting caution.

prnewswire.com · 25 jun

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Industries, Inc. - MDLN

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. ("Medline" or the "Company") (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

globenewswire.com · 23 jun

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Industries, Inc. - MDLN

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

businesswire.com · 23 jun

Access Vascular and Medline Enter Multi-Year Agreement to Launch Cobranded Next-Generation Vascular Access Catheters

BILLERICA, Mass.--(BUSINESS WIRE)--Access Vascular, Inc. (“AVI”), a medical device company specializing in developing advanced vascular access solutions, and Medline, the largest provider of medical-surgical products and supply chain solutions serving all points of care, today announced a multi-year agreement to accelerate the rollout of AVI's next-generation catheters, HydroMID® and HydroPICC®, which recently received an anti-thrombogenic indication from the FDA. The initiative bolsters Medlin.